Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade

Immune checkpoint antibody blockade is an emerging therapeutic option for treating certain cancers including melanoma. This therapy is associated with dermatologic and systemic toxicities, some of which are more severe than others and may require withholding therapy.

[1]  M. Tetzlaff,et al.  Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. , 2017, The American Journal of dermatopathology.

[2]  J. Wargo,et al.  Diverse types of dermatologic toxicities from immune checkpoint blockade therapy , 2017, Journal of cutaneous pathology.

[3]  P. Hwu,et al.  A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1 , 2016, Journal of Immunotherapy for Cancer.

[4]  M. Tetzlaff,et al.  Autoimmune dermatologic toxicities from immune checkpoint blockade with anti‐PD‐1 antibody therapy: a report on bullous skin eruptions , 2016, Journal of cutaneous pathology.

[5]  J. Wolchok,et al.  Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. , 2016, European journal of cancer.

[6]  A. Menter,et al.  Pustular psoriasis eruption with dabrafenib, a BRAF inhibitor , 2016, The Journal of dermatological treatment.

[7]  K. Tsai,et al.  BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. , 2016, Human pathology.

[8]  R. Novoa,et al.  Immunohistochemical analysis of lichenoid reactions in patients treated with anti‐PD‐L1 and anti‐PD‐1 therapy , 2016, Journal of cutaneous pathology.

[9]  G. Linette,et al.  Extensive tumoral melanosis associated with ipilimumab‐treated melanoma , 2016, The British journal of dermatology.

[10]  K. Byth,et al.  Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. , 2016, Journal of the American Academy of Dermatology.

[11]  R. Montironi,et al.  New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors , 2016, Expert opinion on drug metabolism & toxicology.

[12]  T. Jouary,et al.  Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction? , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  P. Nagarajan,et al.  Dermatologic Toxicities to Melanoma Targeted Therapies , 2016 .

[14]  J. Soria,et al.  Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. , 2016, JAMA dermatology.

[15]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[16]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[17]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[18]  David C. Smith,et al.  Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Fernández-Peñas,et al.  A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. , 2015, Melanoma research.

[20]  David C. Smith,et al.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[22]  C. Porta,et al.  PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. , 2015, Cancer treatment reviews.

[23]  J. Luke,et al.  Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. , 2015, JAMA dermatology.

[24]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[25]  M. Garmyn,et al.  Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[26]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[27]  B. Guillot,et al.  First report of ipilimumab‐induced Grover disease , 2014, The British journal of dermatology.

[28]  S. Bagaria,et al.  Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti–PD-1 Therapy , 2014, Cancer Immunology Research.

[29]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[30]  K. Tsai,et al.  Histological Features Associated With Vemurafenib-Induced Skin Toxicities: Examination of 141 Cutaneous Lesions Biopsied During Therapy , 2014, The American Journal of dermatopathology.

[31]  E. Chu,et al.  Vemurafenib‐induced interface dermatitis manifesting as radiation‐recall and a keratosis pilaris‐like eruption , 2014, Journal of cutaneous pathology.

[32]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  K. Tsai,et al.  Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma , 2014, Journal of cutaneous pathology.

[34]  K. Tsai,et al.  Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions , 2014, International journal of dermatology.

[35]  V. Sondak,et al.  Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma , 2013, Nature Reviews Clinical Oncology.

[36]  J. Arrese,et al.  Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases , 2013, Clinical and experimental dermatology.

[37]  A. Hauschild,et al.  Analysis of dermatologic events in vemurafenib-treated patients with melanoma. , 2013, The oncologist.

[38]  C. Berking,et al.  The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network , 2013, PloS one.

[39]  G. Long,et al.  Cutaneous toxicities of RAF inhibitors. , 2013, The Lancet. Oncology.

[40]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[41]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[42]  H. Pehamberger,et al.  Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[44]  A. Maraveyas,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma , 2009, Clinical Cancer Research.

[45]  R. Modlin,et al.  "Dermal dendritic cells" comprise two distinct populations: CD1+ dendritic cells and CD209+ macrophages. , 2008, The Journal of investigative dermatology.

[46]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Michael S. Kuhns,et al.  CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.